starting an AP or patients newly switching to CLZ. Groups A and B will be assessed at a single time point (week 0) whereas Group C will be assessed prospectively at weeks 0, 3, and 12 with the same measures collected. The following clinical measures and metabolic indices are collected at baseline, and if applicable, at follow up visits: the Questionnaire of Eating and Weight Patterns (QEWP), the Dutch Eating Behavior Questionnaire (DEBQ), the Power of Food Scale (POFS), the Positive and Negative Syndrome Scale (PANSS), the Gastrointestinal Symptom Rating Scale (GSRS), Exercise/Physical Activity Evaluation, body mass index, oral glucose tolerance test, lipid profile, and serum clozapine levels. We also collect fecal samples for DNA extraction and microbiome sequencing. We are currently performing a baseline comparison across groups A, B, and C in order to evaluate intrinsic differences between schizophrenia and healthy controls, as well as, effects of new AP exposure versus chronic exposure. The difference between analytical groups (i.e. groups A, B, and C) at different time points (i.e. baseline, week 3 and 6) for variables such as BMI and metabolic parameters marker change are analyzed using two-way repeated measures ANCOVA, including significant covariates. The relationship between different measures, such as body weight and metabolic parameters, GMB composition (abundance of each species), and AIWG will be tested using Spearman's correlation. Analysis of the Operational Taxonomic Unit network generated using QIIME will be further analyzed using linear discriminant analysis (LDA) effect size (LEfSe) method. This method uses LDA scores to estimate the effect size of differentially abundant taxa (at phyla, class or other levels) and ranks the relative difference of microbial taxa that discriminate groups with biological consistency and statistical significance. The GMB composition of within group weight gainers versus non-weight gainer will also be assessed in a subgroup of subjects using LEfSe. Results: To date, 17 patients enrolled (13 patients in group A (9 men, mean±SD age: 31.6 ± 5.1 years; BMI, 31.4 ± 5.5), two control in group B (1 men, mean±SD age: 29.0 ± 1.4 years; BMI, 30.3 ± 0.8), two in group C (1 men, mean±SD age: 30.0 ± 9.9 years; BMI, 25.8 ± 5.6)). Further analyses including GMB composition in each group are now being conducted. We are currently analyzing these individuals for their GMB composition and results will be presented at the SIRS meeting. Discussion: To our knowledge, this is the first study to assess GMB sample in SCZ and investigate the association the GMB and AP-induced metabolic side effects. Our study has the potential to help to unravel the role of GMB in SCZ and AP response. 
T193. CHRONIC HALOPERIDOL TREATMENT INDUCES SIGNIFICANT CHANGES IN

Research Center for Molecular Medicine of the Austrian Academy of Sciences
Background: Positron emission tomography (PET) using radiolabeled ligands selective for the 18 kDa translocator protein (TSPO) is the most widely used technique to assess putative neuroimmune abnormalities in vivo. However, the results of TSPO PET in schizophrenia patients are ambiguous. In particular, the influence of antipsychotic medication exposure has not been definitively tested. We have previously established that chronic exposure to two different antipsychotics resulted in increased density and amoeboid morphology of brain microglia, particularly in the cortex (ACC) and corpus striatum (STR) (Cotel et al., 2015) . Here we explore the consequences of such treatment on TSPO, in relation to changes in microglia. We hypothesize that chronic haloperidol treatment would increase the expression of TSPO in microglia and correlate with increased levels of circulating proinflammatory cytokines. Methods: Adult male Sprague-Dawley rats (12 week-old) were implanted with subcutaneous osmotic mini-pumps (ALZET® 2ML4) delivering a continuous dose of either common vehicle (20% β-cyclodextrin + 5% ascorbic acid) or haloperidol (2mg/kg/d) for 28 days (Kapur et al., 2003) . Plasma was collected before perfusing the animals with 4% buffered PFA. Brains were carefully removed and processed for immunostaining against Iba1 and TSPO. Levels of plasma cytokines were measured using the pro-inflammatory 9-plex panel from Meso Scale Discovery (MSD®). TSPO expression was measured by its area fraction using FIJI software (10 snaps per animal per brain region, 20x magnification) in the ACC, STR, hippocampus (HPC), secondary somatosensory cortex (S2), primary motor cortex (M1). Numbers of resting and amoeboid microglia were determined by unbiased stereology (Gundersen, 1987) in the ACC, STR, and HPC. The Cavalieri estimator (StereoInvestigator 12.0,MBF Bioscience) was used to determine the volume of these regions. Data were analyzed by t-tests corrected for multiple comparisons, using GraphPad Prism 6.0. Results: Only 5 cytokines from the panel were above the limit of detection. Of these, IL-6 is significantly increased in haloperidol-treated animals (+186%, p<.01). IL-10, IL-4, KC/GRO, and TNFα plasma levels were not significantly affected. In parallel, TSPO expression was significantly increased in the ACC (+56%, p<.01), the STR (+77%, p<.01) and the S2 (+158%, p<.001). In the STR, the density of both resting and amoeboid microglia were significantly elevated in the treatment group (+22%, p<.05 and +45%, p<.001, respectively). A 2-way ANOVA revealed a significant interaction between treatment and brain region for amoeboid but not resting microglia. Peripheral IL-6 levels correlated negatively with TSPO levels in the STR in saline and haloperidol-treated groups (r=-0.82 and r=-0.62, respectively, p<.05). In addition, KC/GRO, although not different between groups, correlated positively with TSPO levels in STR in controls (r=0.77, p<.05), but negatively in HPC, M1, and S2 after haloperidol treatment (r=-0.66, r=-0.62, r=-0.6, respectively, p<.05). Discussion: As hypothesized, TSPO expression is significantly affected by chronic haloperidol, with augmented levels in the ACC, STR and S2. These data are in line with an increased TSPO PET signal in medicated schizophrenia patients as compared to matched antipsychotic-naïve patients (Holmes et al., 2016) . Furthermore, these data confirm and extend our prior findings demonstrating that microglial activation is present already after 28 days of exposure to haloperidol and this effect is most prominent in the STR. Further investigations are needed to determine which cell types drive changes in TSPO (glia, endothelium, astrocytes) Background: Prenatal exposure to the viral mimic poly-I:C via the pregnant dam has been shown to lead to a broad spectrum of neuro-psychopathological features phenotypic of schizophrenia, recapitulating the well established link between maternal infection in pregnancy and increased schizophrenia risk in the offspring. We previously showed using longitudinal imaging that prenatal poly-I:C leads postnatally to volumetric brain abnormalities that precede the emergence of behavioral abnormalities (selective attention deficits and excessive response to amphetamine) in adulthood, and that an ultra-low dose of risperidone (RIS) given prior to "symptom" emergence, prevents the emergence of behavioral as well as structural brain deficits. Here we aimed at showing that the efficacy of RIS
